Directly Observed Therapy for Community-Released HIV+ Prisoners

HIV/AIDS Clinical Trial

— Connect  

Official title:

Directly Observed Therapy for Community-Released HIV+ Prisoners

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00786396
• Other study ID #: R01 DA 0179059
• Status: Completed
• Phase: N/A
• First received: November 5, 2008
• Last updated: August 18, 2014
• Start date: July 2004
• Est. completion date: December 2010

Study information

• Verified date: August 2014
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to develop effective interventions for HIV-infected prisoners who are released to the community. The intervention that we will study will be directly observed therapy (DAART/DOT) and we will compare this to the current standard of care that involves self-administered therapy (SAT). All subjects will get transitional case management and all subjects with a prior history of opiate dependence will be offered opiate substitution therapy (buprenorphine or methadone).

Hypotheses:

• At the end of six months those receiving DAART will have a higher level of adherence to HAART as compared to the SAT group.

• The DAART Intervention will result in subjects having lower viral loads and higher CD4 counts as compared to the SAT group.

• At the end of six months, the DAART group will have a lower rate of recidivism to jail/prison as compared to the SAT group.

• Over the year, the DAART group will be more likely to make repeated primary HIV care visits than the SAT group.

Description:

Any individual that is HIV positive and incarcerated for at least a period of 90 days and on antiretroviral medications would be referred to the study by the medical staff of the incarceration facilities prior to release or within 30 days of release an individual would be able to self refer.

Subjects would be screened and consented and interviewed prior to their release from incarceration, on their day of release, and monthly for a period of one year. At the time of their day of release interview, subjects are randomized to either the intervention DAART group or the standard of care SAT group. All subjects would be assessed and offered opiate substitution therapy if there was a prior history of opiate dependency as a means of relapse prevention.

Subjects in DAART would be seen everyday for a period of six months by a team of research assistants who observe the subjects taking their medications, and their last six months would be done as standard of care. Standard of care SAT subjects would continue to take their medications on their own as prescribed. All subjects would be interviewed monthly and quarterly would have laboratory blood tests completed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 151
• Est. completion date: December 2010
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HIV seropositive

• 18 years of age or older

• incarcerated for a minimum of 90days

• living in New Haven or Hartford

• currently on HAART or willing to begin HAART medications

Exclusion Criteria:

• Not meeting inclusion criteria

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV/AIDS
• Substance Abuse

Intervention

Behavioral:
• Directly administered antiretroviral therapy
Daily observation of subjects taking their HIV medications

Locations

Country	Name	City	State
United States	Yale University-Yale Clinical Research	Hartford	Connecticut
United States	Yale University School of Medicine	New Haven	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Yale University

Country where clinical trial is conducted

United States, 

References & Publications (4)

Meyer JP, Qiu J, Chen NE, Larkin GL, Altice FL. Emergency department use by released prisoners with HIV: an observational longitudinal study. PLoS One. 2012;7(8):e42416. doi: 10.1371/journal.pone.0042416. Epub 2012 Aug 3. — View Citation

Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes. Contemp Clin Trials. 2012 Mar;33(2):436-44. doi: 10.1016/j.cct.2011.11.002. Epub 2011 Nov 12. — View Citation

Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care. 2009 Aug;21(8):976-83. doi: 10.1080/09540120802657555. — View Citation

Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health. 2010 Jul;87(4):592-602. doi: 10.1007/s11524-010-9438-4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Virological success, defined as greater than 1 log HIV-1 copies/mL reduction or Viral load less than 400 copies/mL at the end of six months on the intervention.		12 months	No
Secondary	DAART subjects will be more likely to make primary HIV care visits than those receiving SAT.		12	No
Secondary	Lower rate of recidivism and to illicit drug use		12 months	No